Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

@article{Ribas2017OncolyticVP,
  title={Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy},
  author={Antoni Ribas and Reinhard Dummer and Igor J. Puzanov and Ari M Vanderwalde and Robert H. I. Andtbacka and Olivier Michielin and Anthony J. Olszanski and Josep Malvehy and Jonathan Simon Cebon and Eugenio Fernandez and John Munn Kirkwood and Thomas F Gajewski and Lei Chen and Kevin S. Gorski and Abraham A. Anderson and Scott J. Diede and Michael E. Lassman and Jennifer L Gansert and Frank Stephen Hodi and Georgina V Long},
  journal={Cell},
  year={2017},
  volume={170},
  pages={1109-1119.e10}
}
Here we report a phase 1b clinical trial testing the impact of oncolytic virotherapy with talimogene laherparepvec on cytotoxic T cell infiltration and therapeutic efficacy of the anti-PD-1 antibody pembrolizumab. Twenty-one patients with advanced melanoma were treated with talimogene laherparepvec followed by combination therapy with pembrolizumab. Therapy was generally well tolerated, with fatigue, fevers, and chills as the most common adverse events. No dose-limiting toxicities occurred… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 74 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB- IVmelanoma

  • J. Chesney, F. Collichio, +7 authors M Ross
  • Ann. Oncol
  • 2016
Highly Influential
5 Excerpts

Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene

  • A. Ribas, C. Robert, +7 authors A Loboda
  • signature. J. Clin. Oncol
  • 2015
Highly Influential
8 Excerpts

Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma

  • J. Chesney, I. Puzanov, +7 authors R.H.I. Andtbacka
  • J. Clin. Oncol
  • 2017
2 Excerpts

Similar Papers

Loading similar papers…